Is BDTX or RKTO more profitable?

Black Diamond Therapeutics' return on equity of -30.18% beat Rocket One Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Black Diamond Therapeutics N/A -30.18% -23.91% Rocket One Inc. Common Stock N/A -165.25% -143.61%

Which has stronger valuation and earnings, RKTO or AIFC?

Rocket One Inc. Common Stock has higher earnings, but lower revenue than ALT5 Sigma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A ALT5 Sigma $24.84M 3.77 -$344.51M N/A N/A

Is RKTO or RANI more profitable?

Rocket One Inc. Common Stock's return on equity of -165.25% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Rani Therapeutics N/A -206.46% -83.95%

Does the media prefer RKTO or RANI?

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 1 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.00 beat Rocket One Inc. Common Stock's score of -0.25 indicating that Rani Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rani Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, RKTO or PMN?

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A Promis Neurosciences N/A N/A -$39.72M -$14.51 N/A

Is RKTO or PMN more profitable?

Rocket One Inc. Common Stock's return on equity of -165.25% beat Promis Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Promis Neurosciences N/A -237.99% -151.04%

Does the media prefer RKTO or PMN?

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.80 beat Rocket One Inc. Common Stock's score of -0.25 indicating that Promis Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Promis Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate RKTO or TELO?

Rocket One Inc. Common Stock currently has a consensus price target of $5.00, suggesting a potential upside of 362.96%. Given Rocket One Inc. Common Stock's higher possible upside, equities research analysts clearly believe Rocket One Inc. Common Stock is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rocket One Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, RKTO or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is RKTO or TELO more profitable?

Rocket One Inc. Common Stock's return on equity of -165.25% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Rocket One Inc. Common Stock N/A -165.25% -143.61% Telomir Pharmaceuticals N/A -201.23% -172.71%

Does the media refer more to RKTO or TELO?

In the previous week, Rocket One Inc. Common Stock and Rocket One Inc. Common Stock both had 2 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 0.00 beat Rocket One Inc. Common Stock's score of -0.25 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rocket One Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Telomir Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Rocket One Inc. Common Stock (RKTO) Competitors

$1.08 0.00 (0.00%)

As of 06/18/2026 04:00 PM Eastern

Compare

RKTO vs. BDTX, AIFC, RANI, PMN, and TELO

Should you buy Rocket One Inc. Common Stock stock or one of its competitors? MarketBeat compares Rocket One Inc. Common Stock with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rocket One Inc. Common Stock include Black Diamond Therapeutics (BDTX), ALT5 Sigma (AIFC), Rani Therapeutics (RANI), Promis Neurosciences (PMN), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical products" industry.

How does Rocket One Inc. Common Stock compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

Black Diamond Therapeutics has a beta of 3.22, indicating that its stock price is 222% more volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market.

Black Diamond Therapeutics' return on equity of -30.18% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-30.18%	-23.91%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Black Diamond Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 502.41%. Rocket One Inc. Common Stock has a consensus target price of $5.00, indicating a potential upside of 362.96%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Rocket One Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Black Diamond Therapeutics has higher revenue and earnings than Rocket One Inc. Common Stock. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.36	$22.37M	-$0.77	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Rocket One Inc. Common Stock had 2 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 0 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.00 beat Rocket One Inc. Common Stock's score of -0.25 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Neutral
Rocket One Inc. Common Stock	Neutral

Summary

Black Diamond Therapeutics beats Rocket One Inc. Common Stock on 13 of the 15 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to ALT5 Sigma?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Rocket One Inc. Common Stock has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. ALT5 Sigma's return on equity of -68.25% beat Rocket One Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

Rocket One Inc. Common Stock currently has a consensus price target of $5.00, suggesting a potential upside of 362.96%. Given Rocket One Inc. Common Stock's stronger consensus rating and higher possible upside, equities analysts plainly believe Rocket One Inc. Common Stock is more favorable than ALT5 Sigma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Rocket One Inc. Common Stock had 2 more articles in the media than ALT5 Sigma. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 0 mentions for ALT5 Sigma. ALT5 Sigma's average media sentiment score of 0.00 beat Rocket One Inc. Common Stock's score of -0.25 indicating that ALT5 Sigma is being referred to more favorably in the news media.

Company	Overall Sentiment
Rocket One Inc. Common Stock	Neutral
ALT5 Sigma	Neutral

Rocket One Inc. Common Stock has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
ALT5 Sigma	$24.84M	3.77	-$344.51M	N/A	N/A

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 6.3% of ALT5 Sigma shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rocket One Inc. Common Stock has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.71, indicating that its stock price is 71% more volatile than the broader market.

Summary

Rocket One Inc. Common Stock beats ALT5 Sigma on 8 of the 13 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Rani Therapeutics?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Rocket One Inc. Common Stock has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

Rocket One Inc. Common Stock's return on equity of -165.25% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Rani Therapeutics	N/A	-206.46%	-83.95%

Rocket One Inc. Common Stock has higher earnings, but lower revenue than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Rani Therapeutics	$1.63M	59.46	-$29.67M	-$0.41	N/A

Rocket One Inc. Common Stock currently has a consensus price target of $5.00, suggesting a potential upside of 362.96%. Rani Therapeutics has a consensus price target of $8.75, suggesting a potential upside of 1,018.35%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than Rocket One Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Comparatively, 26.7% of Rani Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 1 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.00 beat Rocket One Inc. Common Stock's score of -0.25 indicating that Rani Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rani Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rani Therapeutics beats Rocket One Inc. Common Stock on 9 of the 14 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Promis Neurosciences?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Promis Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. Comparatively, 50.1% of Promis Neurosciences shares are owned by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are owned by company insiders. Comparatively, 1.5% of Promis Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Rocket One Inc. Common Stock's return on equity of -165.25% beat Promis Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Promis Neurosciences	N/A	-237.99%	-151.04%

Rocket One Inc. Common Stock has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market. Comparatively, Promis Neurosciences has a beta of -0.19, indicating that its share price is 119% less volatile than the broader market.

In the previous week, Rocket One Inc. Common Stock had 1 more articles in the media than Promis Neurosciences. MarketBeat recorded 2 mentions for Rocket One Inc. Common Stock and 1 mentions for Promis Neurosciences. Promis Neurosciences' average media sentiment score of 0.80 beat Rocket One Inc. Common Stock's score of -0.25 indicating that Promis Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Promis Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Promis Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Promis Neurosciences	N/A	N/A	-$39.72M	-$14.51	N/A

Rocket One Inc. Common Stock currently has a consensus target price of $5.00, indicating a potential upside of 362.96%. Promis Neurosciences has a consensus target price of $26.50, indicating a potential upside of 151.42%. Given Rocket One Inc. Common Stock's higher possible upside, research analysts clearly believe Rocket One Inc. Common Stock is more favorable than Promis Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Promis Neurosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Summary

Rocket One Inc. Common Stock beats Promis Neurosciences on 8 of the 14 factors compared between the two stocks.

How does Rocket One Inc. Common Stock compare to Telomir Pharmaceuticals?

Rocket One Inc. Common Stock (NASDAQ:RKTO) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Rocket One Inc. Common Stock currently has a consensus price target of $5.00, suggesting a potential upside of 362.96%. Given Rocket One Inc. Common Stock's higher possible upside, equities research analysts clearly believe Rocket One Inc. Common Stock is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Rocket One Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Rocket One Inc. Common Stock's return on equity of -165.25% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

7.1% of Rocket One Inc. Common Stock shares are held by institutional investors. 6.9% of Rocket One Inc. Common Stock shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Rocket One Inc. Common Stock has a beta of 0.89, meaning that its share price is 11% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, meaning that its share price is 124% less volatile than the broader market.

In the previous week, Rocket One Inc. Common Stock and Rocket One Inc. Common Stock both had 2 articles in the media. Telomir Pharmaceuticals' average media sentiment score of 0.00 beat Rocket One Inc. Common Stock's score of -0.25 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rocket One Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telomir Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rocket One Inc. Common Stock beats Telomir Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Get Rocket One Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RKTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RKTO vs. The Competition

Export

Metric	Rocket One Inc. Common Stock	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$24.11M	$3.39B	$6.40B	$12.59B
Dividend Yield	N/A	2.31%	2.68%	5.68%
P/E Ratio	-1.35	19.56	24.53	24.44
Price / Sales	N/A	319.38	575.83	128.73
Price / Cash	N/A	127.04	44.20	55.24
Price / Book	2.70	8.16	10.77	6.58
Net Income	-$12.47M	$23.89M	$3.57B	$337.19M
7 Day Performance	-3.14%	2.54%	0.71%	0.60%
1 Month Performance	80.00%	5.98%	3.94%	5.01%
1 Year Performance	-19.40%	53.51%	28.55%	31.07%

Rocket One Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RKTO Rocket One Inc. Common Stock	1.819 of 5 stars	$1.08 flat	$5.00 +363.0%	-19.4%	$24.11M	N/A	N/A	4
BDTX Black Diamond Therapeutics	2.7284 of 5 stars	$1.70 -1.5%	$10.00 +490.0%	-28.8%	$97.12M	$70M	N/A	90
AIFC ALT5 Sigma	0.1178 of 5 stars	$0.69 -5.5%	N/A	-92.7%	$96.50M	$24.84M	N/A	170	Gap Up
RANI Rani Therapeutics	2.2338 of 5 stars	$0.77 +0.6%	$8.75 +1,032.0%	+54.0%	$95.88M	$1.63M	N/A	110
PMN Promis Neurosciences	4.0293 of 5 stars	$10.53 +4.7%	$26.50 +151.8%	-15.7%	$95.19M	N/A	N/A	5	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RKTO) was last updated on 6/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rocket One Inc. Common Stock (RKTO) Competitors

RKTO vs. BDTX, AIFC, RANI, PMN, and TELO

How does Rocket One Inc. Common Stock compare to Black Diamond Therapeutics?

Summary

How does Rocket One Inc. Common Stock compare to ALT5 Sigma?

Summary

How does Rocket One Inc. Common Stock compare to Rani Therapeutics?

Summary

How does Rocket One Inc. Common Stock compare to Promis Neurosciences?

Summary

How does Rocket One Inc. Common Stock compare to Telomir Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RKTO vs. The Competition

Rocket One Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rocket One Inc. Common Stock (RKTO) Competitors

RKTO vs. BDTX, AIFC, RANI, PMN, and TELO

How does Rocket One Inc. Common Stock compare to Black Diamond Therapeutics?

Which has more risk and volatility, BDTX or RKTO?

Is BDTX or RKTO more profitable?

Do analysts recommend BDTX or RKTO?

Which has higher earnings & valuation, BDTX or RKTO?

Do insiders & institutionals have more ownership in BDTX or RKTO?

Does the media refer more to BDTX or RKTO?

Summary

How does Rocket One Inc. Common Stock compare to ALT5 Sigma?

Is RKTO or AIFC more profitable?

Do analysts rate RKTO or AIFC?

Does the media prefer RKTO or AIFC?

Which has stronger valuation and earnings, RKTO or AIFC?

Do insiders and institutionals hold more shares of RKTO or AIFC?

Which has more volatility & risk, RKTO or AIFC?

Summary

How does Rocket One Inc. Common Stock compare to Rani Therapeutics?

Which has more volatility & risk, RKTO or RANI?

Is RKTO or RANI more profitable?

Which has stronger valuation and earnings, RKTO or RANI?

Do analysts rate RKTO or RANI?

Do insiders and institutionals hold more shares of RKTO or RANI?

Does the media prefer RKTO or RANI?

Summary

How does Rocket One Inc. Common Stock compare to Promis Neurosciences?

Do insiders and institutionals believe in RKTO or PMN?

Is RKTO or PMN more profitable?

Which has more risk & volatility, RKTO or PMN?

Does the media prefer RKTO or PMN?

Which has preferable earnings & valuation, RKTO or PMN?

Do analysts rate RKTO or PMN?

Summary

How does Rocket One Inc. Common Stock compare to Telomir Pharmaceuticals?

Do analysts rate RKTO or TELO?

Which has higher earnings & valuation, RKTO or TELO?

Is RKTO or TELO more profitable?

Do insiders & institutionals believe in RKTO or TELO?

Which has more risk and volatility, RKTO or TELO?

Does the media refer more to RKTO or TELO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RKTO vs. The Competition

Rocket One Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools